SAB Biotherapeutics

SAB Biotherapeutics is a clinical-stage, biopharmaceutical company developing a new class of immunotherapies leveraging fully human polyclonal antibodies. SAB has applied advanced genetic engineering and antibody science to develop transchromosomic (Tc) Bovine that produce fully-human antibodies targeted at specific diseases, including infectious diseases such as COVID-19 and influenza, immune system disorders including type 1 diabetes and organ transplantation, and cancer. The company is headquartered in Sioux Falls, South Dakota.